171 related articles for article (PubMed ID: 37045797)
21. Local Control Rates of Metastatic Renal Cell Carcinoma (RCC) to Thoracic, Abdominal, and Soft Tissue Lesions Using Stereotactic Body Radiotherapy (SBRT).
Altoos B; Amini A; Yacoub M; Bourlon MT; Kessler EE; Flaig TW; Fisher CM; Kavanagh BD; Lam ET; Karam SD
Radiat Oncol; 2015 Oct; 10():218. PubMed ID: 26510665
[TBL] [Abstract][Full Text] [Related]
22. Clinical Outcomes of Patients With Recurrent Lung Cancer Reirradiated With Proton Therapy on the Proton Collaborative Group and University of Florida Proton Therapy Institute Prospective Registry Studies.
Badiyan SN; Rutenberg MS; Hoppe BS; Mohindra P; Larson G; Hartsell WF; Tsai H; Zeng J; Rengan R; Glass E; Katz S; Vargas C; Feigenberg SJ; Simone CB
Pract Radiat Oncol; 2019; 9(4):280-288. PubMed ID: 30802618
[TBL] [Abstract][Full Text] [Related]
23. Toxicity profile of patients treated with proton and carbon-ion therapy for primary nasopharyngeal carcinoma: A systematic review and meta-analysis.
Yahya N; Mohamad Salleh SA; Mohd Nasir NF; Abdul Manan H
Asia Pac J Clin Oncol; 2024 Apr; 20(2):240-250. PubMed ID: 36683266
[TBL] [Abstract][Full Text] [Related]
24. The role of stereotactic body radiotherapy in switching systemic therapy for patients with extracranial oligometastatic renal cell carcinoma.
Onal C; Hurmuz P; Guler OC; Yavas G; Tilki B; Oymak E; Yavas C; Ozyigit G
Clin Transl Oncol; 2022 Aug; 24(8):1533-1541. PubMed ID: 35119653
[TBL] [Abstract][Full Text] [Related]
25. Clinical outcomes and toxicity of proton beam therapy for advanced cholangiocarcinoma.
Makita C; Nakamura T; Takada A; Takayama K; Suzuki M; Ishikawa Y; Azami Y; Kato T; Tsukiyama I; Kikuchi Y; Hareyama M; Murakami M; Fuwa N; Hata M; Inoue T
Radiat Oncol; 2014 Jan; 9():26. PubMed ID: 24422711
[TBL] [Abstract][Full Text] [Related]
26. Clinical Efficacy and Safety of Proton and Carbon Ion Radiotherapy for Prostate Cancer: A Systematic Review and Meta-Analysis.
Li M; Li X; Yao L; Han X; Yan W; Liu Y; Fu Y; Wang Y; Huang M; Zhang Q; Wang X; Yang K
Front Oncol; 2021; 11():709530. PubMed ID: 34712607
[TBL] [Abstract][Full Text] [Related]
27. Hypofractionated proton therapy for non-small cell lung cancer: Ready for prime time? A systematic review and meta-analysis.
Volpe S; Piperno G; Colombo F; Biffi A; Comi S; Mastroleo F; Maria Camarda A; Casbarra A; Cattani F; Corrao G; de Marinis F; Spaggiari L; Guckenberger M; Orecchia R; Alterio D; Jereczek-Fossa BA
Cancer Treat Rev; 2022 Nov; 110():102464. PubMed ID: 36194908
[TBL] [Abstract][Full Text] [Related]
28. Bone-only oligometastatic renal cell carcinoma patients treated with stereotactic body radiotherapy: a multi-institutional study.
Onal C; Guler OC; Hurmuz P; Yavas G; Tilki B; Oymak E; Yavas C; Ozyigit G
Strahlenther Onkol; 2022 Oct; 198(10):940-948. PubMed ID: 35695908
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic outcome and related predictors of stereotactic body radiotherapy for small liver-confined HCC: a systematic review and meta-analysis of observational studies.
Long Y; Liang Y; Li S; Guo J; Wang Y; Luo Y; Wu Y
Radiat Oncol; 2021 Apr; 16(1):68. PubMed ID: 33832536
[TBL] [Abstract][Full Text] [Related]
30. Comparison of particle beam therapy and stereotactic body radiotherapy for early stage non-small cell lung cancer: A systematic review and hypothesis-generating meta-analysis.
Chi A; Chen H; Wen S; Yan H; Liao Z
Radiother Oncol; 2017 Jun; 123(3):346-354. PubMed ID: 28545956
[TBL] [Abstract][Full Text] [Related]
31. Stereotactic Ablative Radiation Therapy (SAbR) Used to Defer Systemic Therapy in Oligometastatic Renal Cell Cancer.
Zhang Y; Schoenhals J; Christie A; Mohamad O; Wang C; Bowman I; Singla N; Hammers H; Courtney K; Bagrodia A; Margulis V; Desai N; Garant A; Choy H; Timmerman R; Brugarolas J; Hannan R
Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):367-375. PubMed ID: 31377159
[TBL] [Abstract][Full Text] [Related]
32. Stereotactic radiation therapy in the strategy of treatment of metastatic renal cell carcinoma: A study of the Getug group.
Meyer E; Pasquier D; Bernadou G; Calais G; Maroun P; Bossi A; Theodore C; Albiges L; Stefan D; de Crevoisier R; Hennequin C; Lagrange JL; Grellard JM; Clarisse B; Licaj I; Habrand JL; Carrie C; Joly F
Eur J Cancer; 2018 Jul; 98():38-47. PubMed ID: 29864737
[TBL] [Abstract][Full Text] [Related]
33. Prospective study of proton-beam radiation therapy for limited-stage small cell lung cancer.
Rwigema JM; Verma V; Lin L; Berman AT; Levin WP; Evans TL; Aggarwal C; Rengan R; Langer C; Cohen RB; Simone CB
Cancer; 2017 Nov; 123(21):4244-4251. PubMed ID: 28678434
[TBL] [Abstract][Full Text] [Related]
34. Stereotactic body radiotherapy and tyrosine kinase inhibitors in patients with oligometastatic renal cell carcinoma: a multi-institutional study.
Onal C; Oymak E; Guler OC; Tilki B; Yavas G; Hurmuz P; Yavas C; Ozyigit G
Strahlenther Onkol; 2023 May; 199(5):456-464. PubMed ID: 36450836
[TBL] [Abstract][Full Text] [Related]
35. Clinical results of carbon-ion radiotherapy for stage I non-small cell lung cancer with concomitant interstitial lung disease: a Japanese national registry study (J-CROS-LUNG).
Okano N; Suefuji H; Nakajima M; Tokumaru S; Kubo N; Yoshida D; Suzuki O; Ishikawa H; Satouchi M; Nakayama H; Shioyama Y
J Radiat Res; 2023 Jun; 64(Supplement_1):i2-i7. PubMed ID: 37036751
[TBL] [Abstract][Full Text] [Related]
36. Proton and carbon ion beam treatment with active raster scanning method in 147 patients with skull base chordoma at the Heidelberg Ion Beam Therapy Center-a single-center experience.
Mattke M; Ohlinger M; Bougatf N; Harrabi S; Wolf R; Seidensaal K; Welzel T; Röder F; Gerum S; Ellerbrock M; Jäkel O; Haberer T; Herfarth K; Uhl M; Debus J
Strahlenther Onkol; 2023 Feb; 199(2):160-168. PubMed ID: 36149438
[TBL] [Abstract][Full Text] [Related]
37. Stereotactic Body Radiotherapy for Stage I Renal Cell Carcinoma: National Treatment Trends and Outcomes Compared to Partial Nephrectomy and Thermal Ablation.
Uhlig A; Uhlig J; Trojan L; Kim HS
J Vasc Interv Radiol; 2020 Apr; 31(4):564-571. PubMed ID: 32127324
[TBL] [Abstract][Full Text] [Related]
38. Radiosurgery for Treatment of Renal Cell Metastases to Spine: A Systematic Review of the Literature.
Smith BW; Joseph JR; Saadeh YS; La Marca F; Szerlip NJ; Schermerhorn TC; Spratt DE; Younge KC; Park P
World Neurosurg; 2018 Jan; 109():e502-e509. PubMed ID: 29038086
[TBL] [Abstract][Full Text] [Related]
39. Factors affecting survival in 37 consecutive patients undergoing de novo stereotactic radiosurgery for contiguous sites of vertebral body metastasis from renal cell carcinoma.
Sellin JN; Reichardt W; Bishop AJ; Suki D; Rhines LD; Settle SH; Brown PD; Li J; Rao G; Chang EL; Tatsui CE
J Neurosurg Spine; 2015 Jan; 22(1):52-9. PubMed ID: 25360530
[TBL] [Abstract][Full Text] [Related]
40. Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch(®) patient registry.
Davis JN; Medbery C; Sharma S; Pablo J; Kimsey F; Perry D; Muacevic A; Mahadevan A
Radiat Oncol; 2015 May; 10():113. PubMed ID: 25975848
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]